# ARMI: Advanced Regenerative Manufacturing Institute

> The Advanced Regenerative Manufacturing Institute \(ARMI\) is a member\-based, nonprofit organization advancing biomanufacturing\.

Generated by Yoast SEO v28.5, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [ReGen Valley Tech Hub](https://www.armiusa.org/initiatives/regen-valley-tech-hub-armi/)
- [Partners](https://www.armiusa.org/initiatives/biofab-startup-lab/partners/)
- [BioFab Startup Lab](https://www.armiusa.org/initiatives/biofab-startup-lab/)
- [About BioFab Startup Lab](https://www.armiusa.org/initiatives/biofab-startup-lab/about-biofab-startup-lab/)
- [BioTrek Programs](https://www.armiusa.org/biofabusa/education-and-workforce-development/biotrekprograms/)

## News
- [ARMI \| BioFabUSA and Members Featured in Wicked STEM 2026 Special Section](https://www.armiusa.org/news/armi-biofabusa-and-members-featured-in-wicked-stem-2026-special-section/): The New Hampshire Union Leader’s Wicked STEM 2026 special section highlights ARMI \| BioFabUSA’s education and workforce efforts alongside innovations from members Safi Biotherapeutics and ASI Life Sciences\.
- [HealthTech Hub Company UltraSight Receives FDA Clearance for AI\-Enabled Cardiac Imaging Tool](https://ultrasight.com/ultrasight-in-cardiac-critical-care/): HealthTech Hub company UltraSight has received FDA clearance for PVAD IQ, an AI\-enabled imaging tool designed to support echocardiography workflows and cardiac critical care imaging\.
- [FDA Grants NeuroGenesis Bio RMAT Designation for NG01 for Treatment of Secondary Progressive Multiple Sclerosis](https://www.einpresswire.com/article/900027352/fda-grants-neurogenesis-bio-rmat-designation-for-ng01-for-treatment-of-secondary-progressive-multiple-sclerosis/)
- [Cellbricks Therapeutics Raises €10 Million to Advance Biofabricated Tissue Implants Toward Clinical Use](https://www.globenewswire.com/news-release/2026/03/25/3262050/0/en/Cellbricks-Therapeutics-Raises-10-Million-New-Capital-to-Move-Living-Tissue-Implants-Toward-the-Clinic.html): Cellbricks Therapeutics has raised €10 million to advance development of biofabricated human tissue implants for regenerative medicine, including soft tissue repair, wound healing, and trauma care applications\.
- [Statement from the ARMI Board of Directors](https://www.armiusa.org/news/statement-from-the-armi-board-of-directors/)

## Careers
- [Test Career \(BioFabUSA Category\)](https://www.armiusa.org/career/test-career-biofabusa-category/): Location: Manchester, NH
- [Test Career \(Armi Category\)](https://www.armiusa.org/career/test-career-armi-category/): Location: Manchester, NH

## RFPs
- [Request for Quotes: ARMI \& ARPA\-H REACT – SC\-Islet Differentiation and Testing](https://www.armiusa.org/rfp/request-for-quotes-armi-arpa-h-react-sc-islet-differentiation-and-testing/): ARMI is seeking quotes from qualified laboratories with unique SC\-islet differentiation protocols to support an ARPA\-H REACT study focused on identifying critical quality attributes for preclinical assessment and manufacturing scale\-up\.

## Optional
- [Sitemap index](https://www.armiusa.org/sitemap_index.xml)